Abbott India Limited (ABBOTINDIA.BO)
INR 30999.3
(4.8%)
INR 30999.3
(4.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 51.93 Billion INR | 14.0% |
| 2022 | 45.55 Billion INR | 7.85% |
| 2021 | 42.24 Billion INR | 9.99% |
| 2020 | 38.4 Billion INR | 8.28% |
| 2019 | 35.46 Billion INR | 20.6% |
| 2018 | 29.4 Billion INR | 21.72% |
| 2017 | 24.16 Billion INR | 17.07% |
| 2016 | 20.63 Billion INR | 27.08% |
| 2015 | 16.24 Billion INR | 18.23% |
| 2014 | 13.73 Billion INR | 20.58% |
| 2013 | 11.39 Billion INR | 25.58% |
| 2012 | 9.07 Billion INR | 13.35% |
| 2011 | 8 Billion INR | 76.49% |
| 2010 | 4.53 Billion INR | 18.42% |
| 2009 | 3.82 Billion INR | 9.23% |
| 2008 | 3.5 Billion INR | 6.11% |
| 2007 | 3.3 Billion INR | -2.97% |
| 2006 | 3.4 Billion INR | 9.71% |
| 2005 | 3.1 Billion INR | -0.56% |
| 2004 | 3.12 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 45.15 Billion INR | 0.0% |
| 2023 Q4 | 51.93 Billion INR | 0.0% |
| 2023 FY | 51.93 Billion INR | 14.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q4 | 45.55 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 41 Billion INR | 0.0% |
| 2022 FY | 45.55 Billion INR | 7.85% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 42.24 Billion INR | 9.99% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 42.24 Billion INR | 0.0% |
| 2021 Q2 | 37.19 Billion INR | 0.0% |
| 2020 Q4 | 38.4 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 34.8 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 38.4 Billion INR | 8.28% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 31.75 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 35.46 Billion INR | 20.6% |
| 2019 Q4 | 35.46 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 29.4 Billion INR | 21.72% |
| 2018 Q4 | 29.4 Billion INR | 0.0% |
| 2018 Q2 | 27.26 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 21.89 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 24.16 Billion INR | 17.07% |
| 2017 Q4 | 24.16 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 20.63 Billion INR | 0.0% |
| 2016 Q2 | 17.92 Billion INR | 0.0% |
| 2016 FY | 20.63 Billion INR | 27.08% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q2 | 14.49 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 16.24 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 16.24 Billion INR | 18.23% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 13.73 Billion INR | 20.58% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 12.14 Billion INR | 0.0% |
| 2014 Q4 | 13.73 Billion INR | 0.0% |
| 2013 Q4 | 11.39 Billion INR | 0.0% |
| 2013 FY | 11.39 Billion INR | 25.58% |
| 2013 Q2 | - INR | -100.0% |
| 2013 Q1 | 10.11 Billion INR | -8.34% |
| 2012 Q4 | 11.04 Billion INR | 21.71% |
| 2012 FY | 9.07 Billion INR | 13.35% |
| 2012 Q3 | 9.07 Billion INR | 0.0% |
| 2011 FY | 8 Billion INR | 76.49% |
| 2011 Q3 | 8 Billion INR | 0.0% |
| 2010 FY | 4.53 Billion INR | 18.42% |
| 2009 FY | 3.82 Billion INR | 9.23% |
| 2008 FY | 3.5 Billion INR | 6.11% |
| 2007 FY | 3.3 Billion INR | -2.97% |
| 2006 FY | 3.4 Billion INR | 9.71% |
| 2005 FY | 3.1 Billion INR | -0.56% |
| 2004 FY | 3.12 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cipla Limited | 327.17 Billion INR | 84.126% |
| Gland Pharma Limited | 106.61 Billion INR | 51.286% |
| GlaxoSmithKline Pharmaceuticals Limited | 35.73 Billion INR | -45.323% |
| Kopran Limited | 7.43 Billion INR | -598.758% |
| Marksans Pharma Limited | 26.8 Billion INR | -93.718% |
| NGL Fine-Chem Limited | 3.55 Billion INR | -1360.75% |
| Pfizer Limited | 42.28 Billion INR | -22.813% |
| Sanofi India Limited | 17.14 Billion INR | -202.863% |
| SMS Pharmaceuticals Limited | 10.34 Billion INR | -402.227% |